<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03481348</url>
  </required_header>
  <id_info>
    <org_study_id>PES-ALS</org_study_id>
    <nct_id>NCT03481348</nct_id>
  </id_info>
  <brief_title>Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis: A Pilot Study With 20 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During the course of ALS most patients develop swallowing deficits. In this pilot study we
      investigate if dysphagia in ALS can be improved by Pharyngeal Electrical Stimulation (PES).
      PES is Communauté Européenne (CE-) certificated and has been approved for treatment of
      neurological, oropharyngeal dysphagia. During PES, electrical stimuli are applied at the
      pharynx via a nasogastral tube with the aim of triggering reorganization processes in damaged
      brain structures. There is evidence of a positive effect of PES in Stroke and Multiple
      Sclerosis patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Penetration Aspiration Scale (PAS) Score</measure>
    <time_frame>day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90</time_frame>
    <description>Degree of Penetration and Aspiration evaluated by fiberendoscopic evaluation of swallowing (FEES)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Swallowing-Quality of Life Score (SWAL-QOL)</measure>
    <time_frame>day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90</time_frame>
    <description>swallowing-specific quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schluckbeeinträchtigungs-Skala (SBS) Score</measure>
    <time_frame>day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90</time_frame>
    <description>Clinical scale to evaluate severity of dysphagia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Oral Intake Scale (FOIS) Score</measure>
    <time_frame>day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90</time_frame>
    <description>Clinical scale to evaluate the impairment of oral food intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysphagia Severity Rating Scale (DSRS) Score</measure>
    <time_frame>day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90</time_frame>
    <description>Clinical scale to evaluate severity of dysphagia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALS-FRS-R)</measure>
    <time_frame>day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90</time_frame>
    <description>Clinical scale to evaluate the severity of symptoms in ALS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90</time_frame>
    <description>Frequency of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Pharyngeal Electrical Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PES for 10 minutes per day on 3 consecutive days in addition to standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pharyngeal Electrical Stimulation</intervention_name>
    <description>Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.</description>
    <arm_group_label>Pharyngeal Electrical Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  possible, probable or definite ALS according to the revised El Escorial criteria
             (Brooks et al. 2000)

          -  age &gt;18 years

          -  able to understand all information and to give full consent according to good clinical
             practice (GCP)

          -  moderate ot severe dysphagia, defined by a mean value (all consistencies) of 4

        Exclusion Criteria:

          -  concurrent participation in another interventional trial

          -  tracheostomy

          -  severe psychiatric disorder or clinically manifest dementia

          -  pulmonal or cardial disorder which constitutes a risk when inserting the tube into the
             pharynx

          -  permanent cardiac pacemaker or defibrillator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Dorst, MD</last_name>
      <phone>+49 731 177</phone>
      <phone_ext>5285</phone_ext>
      <email>johannes.dorst@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Dorst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review.</citation>
    <PMID>11464847</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

